CHEMICAL AND PHYSICAL PROPERTIES
| Solubility | 1 mg/mL |
|---|
COMPUTED DESCRIPTORS
| Molecular Weight | 1304.5 g/mol |
|---|---|
| XLogP3 | -6.4 |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 18 |
| Rotatable Bond Count | 30 |
| Exact Mass | 1303.66079514 g/mol |
| Monoisotopic Mass | 1303.66079514 g/mol |
| Topological Polar Surface Area | 552 Ų |
| Heavy Atom Count | 92 |
| Formal Charge | 0 |
| Complexity | 2720 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011.